In a report released yesterday, Sean Lavin from BTIG maintained a Buy rating on Masimo Corp (NASDAQ: MASI), with a price target of $100. The company’s shares closed yesterday at $91.75.
According to TipRanks.com, Lavin is a 5-star analyst with an average return of 14.9% and a 63.0% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Obalon Therapeutics Inc, Boston Scientific Corp, and Varian Medical Systems.
Masimo Corp has an analyst consensus of Moderate Buy, with a price target consensus of $97.
See today’s analyst top recommended stocks >>
Based on Masimo Corp’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $225 million and quarterly net profit of $367K. In comparison, last year the company earned revenue of $186 million and had a net profit of $45.33 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Masimo Corp. is a medical technology company, which develops, manufactures and markets a variety of noninvasive monitoring technologies. It provide products directly and through distributors and original equipment manufacturers partners to hospitals, emergency medical service providers, long-term care facilities, physician offices, veterinarians and consumers. The company was founded by Joe E. Kiani in May 1989 and is headquartered in Irvine, CA.
